Document:

Employment Contract

 Exhibit 10.11 
  
 November 21st, 2000 
  
 The following 
  
 MANAGING
DIRECTOR CONTRACT 
  
 Has been concluded between 
  
 ACADIA Pharmaceuticals A/S 
 Fabriksparken 58 
 2600 Glostrup 

- hereinafter referred to as the “Company” 
  
 and 
  
 Bo-Ragnar Tolf 
 V. Långgatan 29 
 S-619 35 Trosa 
 Sweden 
  
 - hereinafter referred to as the “Director” 
  
 with effect as from January 1st 2001. 
  

	1.	ASSIGNMENTS AND TASKS 

  

	1.1	The Director is employed as managing Director of the Company and registered as such with the Danish Commerce and Companies Agency. 

  

	1.2	Management restrictions provided for by the law, Company bylaws, Company rules and regulations or by this Contract are to be observed by the Director. Shareholders resolutions are
also to be followed. 

  

	2.	OBLIGATIONS AND RESPONSIBILITY 

  

	2.1	The Director shall in conformity with the rules of the Danish Companies act and the guidelines established by the Board of Directors be responsible for the day-to-day management of
the Company’s total activities. The Director shall manage the Company with the due diligence of a prudent businessman and fulfil exactly all obligations assigned to him by law and by contract. In particular the Director shall ensure that the
Company’s book-keeping is in compliance with the provisions of the law, and that the administration of assets takes place in an appropriate manner. 

  

	2.2	The Director agrees to devote his entire business time, attention and energies to the business and interests of the Company during the term of his employment with the Company. The
Director shall not engage in any other business activity or service in any industry, trade, professional, governmental or academic position during the term of his contract which is competitive with the business of the Company or which would
otherwise be detrimental to, or have an adverse effect on, the Company. The Director shall not without the written approval from the Chairman of the Board of Directors accept any other position during the term of his employment with the Company.

  

	2.3	The Director is not bound to any set working hours. Any and all overtime is covered by his salary, see paragraph 4. 

  

	3.	BUSINESS ACTIVITIES REQUIRING APPROVAL 

  

	3.1	The Director must obtain approval by the Board of Directors for any and all business activities that go beyond the scope of normal company business. Such activities include in
particular: 

  

	 	•	Acquisition, disposal or encumbrance of real-estate property or of rights to real-estate-property; 

  

	 	•	Encumbrance of company assets; 

  

	 	•	Acquisitions, disposal or encumbrance of company rights or holdings; 

  

	 	•	Opening or closing of bank accounts; 

  

	 	•	 Granting of securities, conclusion of contracts or other assumptions of obligation, insofar as such transactions are outside the range of Company’s regular
business activities – and in all cases whenever the individual or total 

  

 2 

	 	 
sum of such transactions exceeds DKK 500,000 (or any other amount determined in writing by the Board of Directors); 

  

	 	•	Entering into loan agreements and other forms of credit or similar assumptions of obligation, especially the acceptance of promissory notes; 

  

	 	•	Hiring and dismissal of employees on management level; 

  

	 	•	Opening and closing down of branch offices and other facilities; 

  

	 	•	Issuance of fixed quotations, participation in invitations to tenders, conclusion of contracts that would commit the Company to amounts higher than DKK 500,000.

  

	4.	SALARY AND BENEFITS 

  

	4.1	The annual salary of the Director amounts to DKK 1,370,000, which shall be payable by 1/12 per month in arrears not later than the 25th of each month. The annual salary may be adjusted at the discretion of the Board of Directors on January 1. 

  

	4.2	The Director shall be entitled to participate in a bonus plan for the company as approved by the board of Directors. This plan shall make the Director eligible to a bonus,
dependent, however, upon individual and company performance. 

  

	5.	TRAVEL EXPENSES 

  

	5.1	The Director shall use the means of transportation that are the most economical to the Company and him. 

  

	5.2	The Director is entitled to recover all properly incurred business travel expenses, entertainment costs and other appropriate costs, against documentation of the incurrence of such
expenses, in accordance with the Company’s policies for reimbursement of such expenses. 

  

	6.	PENSION AND INSURANCE 

  

	6.1	The Company will pay an amount equal to 10% of the annual salary, of. paragraph 4.1, into a company pension scheme for the Director. 

  

	6.2	All tax implications, if any, to the Director of the Company’s contributions to the Director’s pension scheme shall be for the Director’s own account and shall not be
reimbursed by the Company. 

  

	7	VACATION 

  

	7.1	The Director is entitled to 5 weeks’ vacation (25 working days), continuous or divided, within each calendar year. 

  

 3 

	7.2	Subject to the prior notice from the Director to the Chairman of the Board of Directors the Director decides the time of the vacation, always provided, however, that this vacation
shall be taken at a time which is convenient for the operation of the Company. 

  

	7.3	The Director shall not be covered by the provisions of the Danish Holiday with Pay Act (Ferieloven). 

  

	8.	SECRECY OBLIGATIONS 

  

	8.1	The Director shall be obliged during his employment as well as after termination – irrespective of the cause – to observe secrecy with regard to all information of a
confidential or proprietary nature concerning the Company and its shareholders that he has acquired during the duration of the contract. 

  

	8.2	On termination of the Contract – irrespective of the cause – the Director shall return all assets and material including all copies belonging to the Company. The Director
shall have no lien on such assets and material for any claims towards the Company 

  

	9.	TERMINATION AND DURATION OF CONTRACT 

  

	9.1	This employment contract replaces all prior contracts concluded between the parties. 

  

	9.2	This employment contract is effective as of January 1, 2001 and shall continue to be in effect through November 30, 2003 after which date the employment contract shall be terminated
without further notice. 

  
 The employment contract
may be extended by agreement between the parties for one year at a time. The employment contract may under no circumstances be extended beyond November 30, 2007, at which time the employment contract shall be terminated without further notice.

  

	9.3	As of any first day of a month the contract may be terminated by the Company subject to a six months notice. In the event that the Company at any time during the notice period
definitively suspends the Director from his working obligations then the Director shall be entitled within 30 days after such suspension to request that the Company in full settlement of all the Company’s obligations to the Director hereunder
pay an amount equal to two thirds of the aggregate of the salary and benefits, cf. paragraph 4, and the contribution to the Directors pensions scheme, cf. paragraph 6.1, for the remaining notice period. 

  

	9.4	If the Director has been continuously prevented by illness from discharging his obligations for an aggregate period of more than four months within a six months period, or if he is
suffering from an infirmity which for an aggregate period of more than four months within a six months period makes him unsuited for the work required by his position, he may be dismissed from his position at three months’ notice on the first
day of a month. 

  

	9.5	 If the Director deceases during his employment, the Company shall pay his salary to the end of the month in which the death occurred. In addition, the Company shall
pay 

  

 4 

	 	 
six months post-service salary and value of benefits, cf. paragraph 4, to the Directors widow, if any, or to his children under the age of 21 years.

  

	9.6	If the Director is in material breach of any of his obligations in accordance with the terms of his employment, the Board of Directors can dismiss him without notice to retire
immediately or at any time fixed by the Board of Directors. In accordance with Danish law he is liable to compensate the Company for any losses it may have incurred as a consequence of breach of his obligations. 

  

	9.7	Termination of the contract must occur in writing in order to be valid. 

  

	10.	PROHIBITION OF COMPETITION 

  

	10.1	As long as the Director is employed by the Company and for a period of 12 months after the Director has retired, the following non-competition clause applies worldwide.

  

	10.2	In case the Director retires, except he is given notice by the Company without reasonable cause, or except if the Director himself retires and the Company has given reasonable cause
for such retirement, the Director is not entitled to be engaged in activities competing with the interest of the Company or any affiliate thereof. 

  

	10.3	Violation of the non-competition clause can be countered by provisional injunction without security and violation triggers payment by the Director of DKK 500,000 each time a
violation takes place. If the violation is of continuing nature it shall be considered that one violation has occurred for each beginning of a calendar month on which violation is continuing. Payment of the agreed penalty does not result in the
termination of the non-competition clause. If the direct or indirect loss of the Company exceeds the agreed penalty the Director is obliged to pay compensation in full to the Company. 

  

	11.	LAW AND VENUE 

  

	11.1	This Contract shall be governed by Danish law. However, the provisions of the Danish Salaried Employees Act (Funktionærloven) do not apply to the Contract.

  

	11.2	Any dispute concerning contractual matters or the understanding of this Contract shall, provided the parties fail to agree, be decided by the Maritime and Commercial Court in
Copenhagen with access to a court of appeal. 

  

	12.	FINAL PROVISIONS 

  

	12.1	The parties attest to the fact that no oral agreements outside this Contract have been made. Any alterations of or supplements to this Contract must be in written form in order to
be valid. Alteration of this provision is likewise required to be in written form. 

  

	12.2	 Should any single provision within this Contract be invalid, that shall have no effect upon the validity of the remaining provisions. The parties shall be
responsible for 

  

 5 

	 	 
replacing the invalid provision with a valid one that comes as close as possible to achieving the desired economic aim. 

  

	13.	SIGNATURE 

  

	13.1	The Contract is drawn in two copies, the original to be kept by the Company and the duplicate to be kept by the Director signed by the Company. 

  

					
	 Date: Dec. 13, 2000
  
	 	 	 	 Date:
 for ACADLA Pharmaceuticals A/S

			
	 /s/ BO-RAGNAR TOLF
	 	 	 	 /s/ ULI HACKSELL

	
	 	 	 	

	 Bo-Ragnar Tolf
	 	 	 	 Uli Hacksell

  

 6Amendment to Collaboration Research, Development & License Agreement

 Exhibit 10.13 
  
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4), 
 200.83 and 230.406 
  
 AMENDMENT TO 
 COLLABORATIVE RESEARCH, DEVELOPMENT 
 AND LICENSE AGREEMENT 
  
 THIS AMENDMENT TO
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (the “Amendment”) is entered into as of March
27, 2003 (the “Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”) with
offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and ALLERGAN SALES LLC a Delaware limited liability company, as successor in interest of VISION PHARMACEUTICALS
L.P., a Texas limited partnership (“Allergan”), with offices at 2525 Dupont Drive, Irvine, CA 92623, and ALLERGAN, INC., a Delaware corporation, solely as
guarantor of the performance under this Agreement by Allergan. 
  
 RECITALS 
  
 WHEREAS, the parties previously entered into that certain Collaborative Research, Development and License Agreement, dated September 24, 1997 (the “1997 Agreement”), pursuant to
which the parties conducted collaborative research regarding, among other things, receptor selective compounds with the goal of establishing drug discovery programs related to such receptor selective compounds; and 
  
 WHEREAS, this Amendment provides for further research
on [...***...] receptors pursuant to the terms of the 1997 Agreement and the terms set forth below (the “[...***...] Research Program”); and 
  
 WHEREAS, ACADIA and Allergan, Inc. are concurrently
entering into a new Collaborative Research, Development and License Agreement, dated of even date herewith (the “2003 Agreement”), which shall govern certain aspects of this Amendment as set forth below. 
  
 NOW THEREFORE, in consideration of the
foregoing and the covenants and premises contained in this Agreement, the parties hereby amend the 1997 Agreement as follows: 
  

	1.	[...***...] RESEARCH PROGRAM. The parties agree to continue their efforts under the 1997 Agreement, as amended hereby, with respect
only to [...***...] receptors and, in that regard, to conduct the [...***...] Research Program in accordance with the research plan currently in effect under the 1997 Agreement, as may be updated from time to time by the Joint Research
Committee pursuant to Section 3.2 of the 2003 Agreement (the “[...***...] Research Plan”) during the Research Term (as defined in the 2003 Agreement). From and after the Amendment Effective Date, no
further work with respect to any receptors or receptor subtypes shall be conducted under the Collaboration (as defined in the 1997 Agreement), other than work with respect to [...***...] receptors pursuant to the [...***...] Research
Program, and all of Allergan’s rights under the 1997 Agreement with respect to such receptors and receptor subtypes (other than [...***...] receptors) shall expire upon expiration of the Research Term under the 1997 Agreement, subject to
surviving obligations under Section 11.4 of the 1997 Agreement. In addition, all of ACADIA’s rights to any ACADIA Designated Use shall expire as of the date of this Amendment. 

  
 * Confidential Treatment Requested 

	        	Except as specifically provided in this Amendment, the work conducted under and results of the [...***...] Research Program shall be subject to the terms of the 1997
Agreement, as amended hereby, and, to the extent appropriate for such purpose, references in the 1997 Agreement to “Research Plan” shall include the [...***...] Research Plan and references in the 1997 Agreement to “Research
Term” shall include the Research Term (as defined in the 2003 Agreement) with respect to the [...***...] Research Program.  

  

	2.	RESEARCH MANAGEMENT. The [...***...] Research Program shall be managed by the Joint Research Committee as set forth in Section 2 of the
2003 Agreement. 

  

	3.	RESEARCH FUNDING. Research efforts and funding for the [...***...] Research Program shall be as provided in Section 8.4 of the 2003
Agreement. 

  

	4.	EXCLUSION OF CERTAIN PROVISIONS OF THE 1997 AGREEMENT.
Sections 5.3 and 14.8 of the 1997 Agreement are hereby terminated and shall be of no further force and effect. 

  

	5.	FULL FORCE AND EFFECT. Except as specifically amended by this Amendment, the 1997 Agreement shall remain in
full force and effect. If there is any inconsistency or conflict between any provision in this Amendment and any provision in the 1997 Agreement, the provision in this Amendment shall control. 

  

	6.	MISCELLANEOUS. This Amendment may be signed in counterparts, each of which shall be deemed an original, all of which taken together shall be deemed one
instrument. This Amendment shall be governed by the laws of the State of California as such laws are applied to contracts entered into or to be performed entirely within such state. 

  
 * Confidential Treatment Requested 
  
  

 2. 

 IN WITNESS WHEREOF, the parties hereto have duly
executed this AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT. 
  

			
	 ACADIA PHARMACEUTICALS INC.
	 	ALLERGAN SALES LLC, a Delaware limited liability company, as successor in interest of
	 	 	VISION PHARMACEUTICALS L.P.,
	 	 	 A Texas limited partnership, dba Allergan,
 by
Allergan General, Inc.,
 its general partner

  

							
	By:	 	/s/    ULI HACKSELL	  	By:	 	/s/    JL EDWARDS
	 	 	
	 	 	 	

	Name:	 	Uli Hacksell	  	Name:	 	JL Edwards 
	 	 	
	 	 	 	

	Title:	 	CEO	  	Title:	 	VP
	 	 	
	 	 	 	

			
	 Guarantee of performance by:
	  	 	 	 
			
	ALLERGAN, INC.	  	 	 	 
				
	By:	 	/s/    LESTER J. KAPLAN 	  	 	 	 
	 	 	
	 	 	 	 
	Name:	 	Lester J. Kaplan	  	 	 	 
	 	 	
	 	 	 	 
	Title:	 	Corp V.P	  	 	 	 
	 	 	
	 	 	 	 

  

 3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]